What is BDSI P/E ratio?

BioDelivery Sciences International, Inc.'s P/E ratio is 6.82. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.

What is BDSI return on equity (ROE)?

BioDelivery Sciences International, Inc.'s return on equity (ROE) is 57.33%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.

What is BioDelivery Sciences International, Inc.'s market cap?

BioDelivery Sciences International, Inc. has a market capitalization of $577.05M.

NASDAQ · Drug Manufacturers - Specialty & Generic

BioDelivery Sciences International, Inc. (BDSI) Stock

Q: What is BioDelivery Sciences International, Inc. (BDSI) stock price today?

BioDelivery Sciences International, Inc. (BDSI) is currently trading at $5.59, down 0.09% today.

$5.59 -0.09% NASDAQ: BDSI Healthcare

Valuation

Metric	Value
Price	$5.59
Market Cap	$577.05M
P/E Ratio	6.82
P/B Ratio	3.07
P/S Ratio	3.46
EPS (TTM)	$0.82
52-Week High	$5.62
52-Week Low	$2.50
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	57.33%
ROA	26.14%
ROCE	15.33%
Gross Margin	85.98%
Operating Margin	22.27%
Net Margin	50.90%
Debt/Equity	0.31
Current Ratio	2.45

Annual Financials (USD)

Metric	2017	2018	2019	2020	2021
Revenue	$62.0M	$56.0M	$111.0M	$156.0M	$167.0M
Operating Profit	$-29.0M	$-24.0M	$4.0M	$33.0M	$37.0M
Net Profit	$5.0M	$-34.0M	$-15.0M	$26.0M	$85.0M
EPS	$0.09	$-0.54	$-0.18	$0.24	$0.82
Op Margin	-47.5%	-42.5%	3.4%	21.1%	22.3%

Balance Sheet (USD)

Metric	2017	2018	2019	2020	2021
Total Assets	$88.0M	$109.0M	$183.0M	$240.0M	$325.0M
Total Liabilities	$79.0M	$79.0M	$113.0M	$132.0M	$137.0M
Cash	$21.0M	$44.0M	$64.0M	$112.0M	$114.0M
Borrowings	$48.0M	$52.0M	$59.0M	$78.0M	$59.0M

Cash Flow (USD)

Metric	2017	2018	2019	2020	2021
Operating Cash Flow	$-32.0M	$-24.0M	$11.0M	$25.0M	$41.0M
Investing Cash Flow	$-12.0M	$-4.0M	$-31.0M	$0	$-7.0M
Financing Cash Flow	$-3.0M	$-1.0M	$2.0M	$3.0M	$-11.0M
Net Cash Flow	$-11.0M	$23.0M	$20.0M	$48.0M	$3.0M
Free Cash Flow	$-38.0M	$-26.0M	$11.0M	$25.0M	$41.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.03
EV / EBITDA	11.71
FCF Yield	7.04%
Quick Ratio	2.17
Interest Coverage	4.95
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACCDAccolade, Inc.	$7.02	+0.00%	-5.28	$575.59M	0.00%
ALIMAlimera Sciences, Inc.	$5.54	-0.18%	-7.01	$301.29M	0.00%
APENApollo Endosurgery, Inc.	$10.00	+0.00%	-10.20	$579.72M	0.00%
EXAIExscientia plc	$4.84	—	-3.06	$633.18M	0.00%
GRALVGRAIL, Inc. Common Stock	$18.63	+8.19%	—	$579.39M	0.00%

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (BDSI) is a specialized pharmaceutical firm dedicated to the advancement and commercialization of therapeutic products designed for long-term health conditions, serving markets both within the United States and internationally. The company's product offerings leverage its proprietary BioErodible MucoAdhesive drug delivery system—a slender, dissolving polymer film intended for application to the inner cheek—in addition to other drug administration methodologies. Its portfolio includes several key products: BELBUCA, a buprenorphine buccal film, is utilized for the ongoing management of persistent pain. Symproic functions as a peripherally acting mu-opioid receptor antagonist, specifically addressing opioid-induced constipation in adult patients suffering from chronic non-cancer pain. This also covers individuals whose chronic pain is a result of prior cancer or its treatment, provided they do not require frequent increases in opioid dosage. ELYXYB, an oral solution containing celecoxib, provides treatment for adult migraines, irrespective of the presence of an aura. ONSOLIS, a soluble fentanyl film administered buccally, is intended for the management of sudden, severe "breakthrough" pain experienced by cancer patients. Founded in 1997, BioDelivery Sciences International, Inc. is headquartered in Raleigh, North Carolina. As of March 18, 2022, the company operates as a subsidiary of Collegium Pharmaceutical, Inc.

BioDelivery Sciences International, Inc. is headquartered in US.

BioDelivery Sciences International, Inc. (BDSI) stock trades at $5.59 with a market capitalization of $577.05M. The stock is valued at a price-to-earnings (P/E) ratio of 6.82, price-to-book of 3.07, price-to-sales of 3.46. Over the past 52 weeks the stock has ranged between $2.50 and $5.62, and currently trades at or near its 52-week high.

On profitability, BioDelivery Sciences International, Inc. generates a return on equity (ROE) of 57.33%, above the typical market range of roughly 12-15%, return on capital employed of 15.33%, an operating margin of 22.27%, a net profit margin of 50.90%.

Official website: www.bdsi.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1166.51 -1.36% JNJ Johnson & Johnson $248.61 -5.73% ABBV AbbVie Inc. $274.31 -2.42% MRK Merck & Company, Inc. Common Stock (new) $141.98 -2.39% UNH UnitedHealth Group Incorporated Common Stock (DE) $377.76 -0.20% NVS Novartis AG $142.41 -0.99% TMO Thermo Fisher Scientific Inc $663.04 +0.12% AZN AstraZeneca PLC $155.82 -1.59% AMGN Amgen Inc. $412.84 -1.13% GILD Gilead Sciences, Inc. $147.92 -1.67% ABT Abbott Laboratories $102.67 +0.83% NVO Novo Nordisk A/S $38.06 -1.35%

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.